These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 23784264)
1. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Shin KH; Choi MH; Lim KS; Yu KS; Jang IJ; Cho JY Clin Pharmacol Ther; 2013 Nov; 94(5):601-9. PubMed ID: 23784264 [TBL] [Abstract][Full Text] [Related]
2. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471 [TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371 [TBL] [Abstract][Full Text] [Related]
4. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers. Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714 [TBL] [Abstract][Full Text] [Related]
5. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Chaobal HN; Kharasch ED Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619 [TBL] [Abstract][Full Text] [Related]
6. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753 [TBL] [Abstract][Full Text] [Related]
7. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680 [TBL] [Abstract][Full Text] [Related]
8. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin. Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201 [TBL] [Abstract][Full Text] [Related]
9. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473 [TBL] [Abstract][Full Text] [Related]
10. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557 [TBL] [Abstract][Full Text] [Related]
11. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608 [TBL] [Abstract][Full Text] [Related]
12. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment. Fenske M Br J Clin Pharmacol; 2007 May; 63(5):632; author reply 633. PubMed ID: 17094779 [No Abstract] [Full Text] [Related]
13. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Chen M; Nafziger AN; Bertino JS Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping. Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901 [TBL] [Abstract][Full Text] [Related]
15. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females. Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515 [TBL] [Abstract][Full Text] [Related]
16. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659 [TBL] [Abstract][Full Text] [Related]
17. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711 [TBL] [Abstract][Full Text] [Related]
18. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530 [TBL] [Abstract][Full Text] [Related]